RESPONSE TO MESNA, DOXORUBICIN, IFOSFAMIDE, AND DACARBAZINE IN 108 PATIENTS WITH METASTATIC OR UNRESECTABLE SARCOMA AND NO PRIOR CHEMOTHERAPY

被引：242
|
作者：
ELIAS, A
RYAN, L
SULKES, A
COLLINS, J
AISNER, J
ANTMAN, KH
机构：
[1] HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV BIOSTAT,BOSTON,MA 02115
[2] UNIV MARYLAND,CTR CANC,DEPT ONCOL,BALTIMORE,MD 21201
[3] NCI,CLIN PHARMACOL BRANCH,BETHESDA,MD 20205
来源：
JOURNAL OF CLINICAL ONCOLOGY | 1989年 / 7卷 / 09期
关键词：
D O I：
10.1200/JCO.1989.7.9.1208
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1208 / 1216
页数：9
相关论文
共 50 条
  • [21] Two Consecutive Cases of Platinum-Refractory Pulmonary Pleomorphic Carcinoma that Showed Dramatic Responses to MAID (Mesna, Doxorubicin, Ifosfamide and Dacarbazine) Chemotherapy
    Lee, Keun-Wook
    Kim, Yu Jung
    Kim, Jee Hyun
    Bang, Soo-Mee
    Chung, Jin-Haeng
    Lee, Jong Seok
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (03) : 430 - 433
  • [22] PHASE-II TRIAL OF IFOSFAMIDE WITH MESNA IN PREVIOUSLY TREATED METASTATIC SARCOMA
    ANTMAN, KH
    MONTELLA, D
    ROSENBAUM, C
    SCHWEN, M
    CANCER TREATMENT REPORTS, 1985, 69 (05): : 499 - 504
  • [23] Low-dose gemcitabine doxorubicin and docetaxel combination in patients with advanced/unresectable/metastatic sarcoma who failed prior chemotherapy: Updated analysis.
    Narasimhan, Vivek
    Hu, James
    Sankhala, Kamalesh Kumar
    Quon, Doris V.
    Menendez, Lawrence
    Fernandez, Lita
    Chua, Victoria S.
    Chawla, Sant P.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [24] A PHASE-II STUDY OF IFOSFAMIDE MESNA WITH DOXORUBICIN FOR ADULT SOFT-TISSUE SARCOMA
    CANTWELL, BMJ
    CARMICHAEL, J
    GHANI, S
    HARRIS, AL
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1988, 21 (01) : 49 - 52
  • [25] A Southwest Oncology Group and Cancer and Leukemia Group B Phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma
    Antman, K
    Crowley, J
    Balcerzak, SP
    Kempf, RA
    Weiss, RB
    Clamon, GH
    Baker, LH
    CANCER, 1998, 82 (07) : 1288 - 1295
  • [26] Phase II study of ifosfamide and mesna in patients with metastatic breast cancer
    Walters, RS
    Holmes, FA
    Valero, V
    Esparza-Guerra, L
    Hortobagyi, GN
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1998, 21 (04): : 413 - 415
  • [27] CHEMOTHERAPY AND CARBOPLATIN IFOSFAMIDE MESNA IN RECURRENT AND METASTATIC SQUAMOUS-CELL CARCINOMA OF THE CERVIX
    BOHM, W
    SCHLOSSHAUER, P
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 1993, 254 (1-4) : 1048 - 1050
  • [28] Outcomes of metastatic synovial sarcoma with doxorubicin, pazopanib, and ifosfamide therapy.
    Coelho, Priscila Barreto
    Costa, Philippos Apolinario
    Freire, Andrea P. Espejo
    Kwon, Deukwoo
    Jonczak, Emily
    D'Amato, Gina Z.
    Trent, Jonathan C.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [29] Phase 2 study of gemcitabine, docetaxel, and doxorubicin in patients with advanced, unresectable, and/or metastatic sarcoma who have failed prior therapies.
    Hendifar, Andrew Eugene
    Chawla, Neal S.
    Sankhala, Kamalesh Kumar
    Zhang, Xiao
    Quon, Doris V.
    Chua, Victoria S.
    Fernandez, Lita
    Mendanha, William E.
    Chawla, Sant P.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [30] Transitioning adriamycin ifosfamide mesna (AIM) chemotherapy in sarcoma patients to the outpatient setting: Evaluation of outpatient chemotherapy in an oncology care model setting.
    Banh, Cindy
    Valsvik, Kendall
    Arredondo, Alejandra
    Notbohm, Kassie
    Kumar, Abhijeet
    Cranmer, Lee D.
    Kraft, Andrew S.
    Abraham, Ivo
    McBride, Ali
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345